LOS ANGELES--(BUSINESS WIRE)--
Goldberg Law PC announces that it is investigating Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company”) (NYSE: TARO) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Taro shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].
The investigation revolves around whether Taro and certain of its officers and/or directors violated federal securities laws. On September 9, 2016, Taro announced that it and two of its senior officers received grand jury subpoenas for a federal antitrust investigation into generic drug pricing. When this news was announced to the public, shares of Taro dropped in value.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006034/en/
